MajerusPW, BrozeGJJr, MiletichJP, TollefsenDM. Anticoagulant, thrombolytic, and antiplatelet drugs. In: GoodmanALS, LimbirdLE, MillinoffPB, RuddonRW, GilmanAG, eds. Goodman and Gilman's Pharmacological Basis of Therapeutics. 9th edn.New York: McGraw-Hill, 1996:1341–59
2.
AithalGP, DayCP, KestevenPJ, DalyAK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet1999;353:717–9
3.
DionisioD, MininniS, BartolozziD, EspertiF, VivarelliA, LeonciniF. Need for increased dose of warfarin in HIV patients taking nevirapine. AIDS2001;15:277–8
4.
BonoraS, LanzafameM, D'AvolioA, Drug interactions between warfarin and efavirenz or lopinavir–ritonavir in clinical treatment. Clin Infect Dis2008;46:146–7
5.
ĆedricA, OlivierT. Amprenavir or fosamprenavir plus ritonavir in HIV infection pharmacology, efficacy and tolerability profile. Drugs2005;65:633–59
